Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group. Rosenstock J, et al. Among authors: kravitz b. Diabetes Obes Metab. 2006 Jan;8(1):49-57. doi: 10.1111/j.1463-1326.2005.00541.x. Diabetes Obes Metab. 2006. PMID: 16367882 Clinical Trial.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Kahn SE, et al. Among authors: kravitz bg. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4. N Engl J Med. 2006. PMID: 17145742 Free article. Clinical Trial.
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Kahn SE, et al. Among authors: kravitz bg. Diabetes Care. 2008 May;31(5):845-51. doi: 10.2337/dc07-2270. Epub 2008 Jan 25. Diabetes Care. 2008. PMID: 18223031 Free article. Clinical Trial.
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Kahn SE, et al. Among authors: kravitz bg. Diabetes Care. 2010 Jan;33(1):177-83. doi: 10.2337/dc09-1661. Epub 2009 Oct 6. Diabetes Care. 2010. PMID: 19808911 Free PMC article. Clinical Trial.
42 results